Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry
Abstract There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national r...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/86e2f28a42fa4d5789e3d0e70e0830b6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:86e2f28a42fa4d5789e3d0e70e0830b6 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:86e2f28a42fa4d5789e3d0e70e0830b62021-12-02T17:03:50ZRepeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry10.1038/s41598-021-94203-72045-2322https://doaj.org/article/86e2f28a42fa4d5789e3d0e70e0830b62021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94203-7https://doaj.org/toc/2045-2322Abstract There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5–71.5%, range 0–100%) and decreased to 0.3% (IQR 0–5.4%, range 0–100%) by May and June and 0% (IQR 0–1.3%, range 0–36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care.Steven M. BradleySophia Emmons-BellR. Kannan MutharasanFatima RodriguezDivya GuptaGregory RothTy J. GluckmanRashmee U. ShahTracy Y. WangRohan KheraPamela N. PetersonSandeep DasNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-4 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Steven M. Bradley Sophia Emmons-Bell R. Kannan Mutharasan Fatima Rodriguez Divya Gupta Gregory Roth Ty J. Gluckman Rashmee U. Shah Tracy Y. Wang Rohan Khera Pamela N. Peterson Sandeep Das Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| description |
Abstract There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5–71.5%, range 0–100%) and decreased to 0.3% (IQR 0–5.4%, range 0–100%) by May and June and 0% (IQR 0–1.3%, range 0–36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care. |
| format |
article |
| author |
Steven M. Bradley Sophia Emmons-Bell R. Kannan Mutharasan Fatima Rodriguez Divya Gupta Gregory Roth Ty J. Gluckman Rashmee U. Shah Tracy Y. Wang Rohan Khera Pamela N. Peterson Sandeep Das |
| author_facet |
Steven M. Bradley Sophia Emmons-Bell R. Kannan Mutharasan Fatima Rodriguez Divya Gupta Gregory Roth Ty J. Gluckman Rashmee U. Shah Tracy Y. Wang Rohan Khera Pamela N. Peterson Sandeep Das |
| author_sort |
Steven M. Bradley |
| title |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| title_short |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| title_full |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| title_fullStr |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| title_full_unstemmed |
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry |
| title_sort |
repeated cross-sectional analysis of hydroxychloroquine deimplementation in the aha covid-19 cvd registry |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/86e2f28a42fa4d5789e3d0e70e0830b6 |
| work_keys_str_mv |
AT stevenmbradley repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT sophiaemmonsbell repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT rkannanmutharasan repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT fatimarodriguez repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT divyagupta repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT gregoryroth repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT tyjgluckman repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT rashmeeushah repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT tracyywang repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT rohankhera repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT pamelanpeterson repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry AT sandeepdas repeatedcrosssectionalanalysisofhydroxychloroquinedeimplementationintheahacovid19cvdregistry |
| _version_ |
1718381859513040896 |